Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

Transl Cancer Res. 2019 Mar;8(Suppl 2):S79-S83. doi: 10.21037/tcr.2018.08.23.

Authors

Caterina Mecca¹, Valentina Bertaglia¹, Silvia Novello¹

Affiliation

¹ Oncology Department, San Luigi Hospital, University of Turin, Orbassano, TO, Italy.

No abstract available

Publication types

Editorial
Comment